New patent for Sanofi-aventis Us drug SOLIQUA 100/33

Annual Drug Patent Expirations for SOLIQUA+100%2F33
Annual Drug Patent Expirations for SOLIQUA+100%2F33

Soliqua 100/33 is a drug marketed by Sanofi-aventis Us
and is included in one NDA. It is available from one supplier.

The generic ingredient in SOLIQUA 100/33 is insulin glargine; lixisenatide. One supplier is listed for this compound. Additional details are available on the insulin glargine; lixisenatide profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs,
contact admin@DrugPatentWatch.com
or visit www.DrugPatentWatch.com